The Infectious Diseases Diagnostics Market To Slither Amidst Covid-19, To Pick Up Pace Post-Covid-19, Reach US$ 1503.8 Million

21/dic/2020 15:04:25 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

According to the latest market report published by Persistence Market Research, titled “Global Market Study on  Infectious Diseases Diagnostics : Increasing Demand for Evidence-Based Treatment to Boost Demand for Infectious Diagnostic Testing during Forecast Period”. The global market for infectious diseases diagnostics is estimated to reach  US $ 876.6 Mn in 2016 from US $ 827.7 Mn in 2015  owing to increasing demand for diagnostic kits caused by rising incidence rate of infectious diseases.

The global infectious disease diagnostics market is expected to reach  US $ 1503.8 Mn by 2024 . Sexually Transmitted Diseases (STDs) segment is expected to continue to remain the largest segment by diseases indication accounting for US $ 282.4 Mn in terms of revenue in 2016, a Y - o - Y increase of 7.0% over 2015. The chlamydia diagnostics test kits are expected to gain upward momentum in 2016, growing at 8.9% in terms of revenue, the fastest among disease indication segment.

Get Sample Copy of Report @  https://www.persistencemarketresearch.com/samples/11413

Company Profiled

  • Becton Dickinson & Company
  • Cepheid, Inc.
  • Abbott Laboratories
  • bioMerieux SA
  • Hologic, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Roche Diagnostics
  • Alera Inc.
  • DiaSorin SpA
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.

Get To Know Methodology of Report @  https://www.persistencemarketresearch.com/methodology/11413

Cell cultures segment is expected to register highest CAGR in terms of revenue, by test type accounting for US $ 311.4 Mn in terms of revenue in 2016. The affordability of cell culture kits and large applications in diagnosis of several infectious diseases is gaining traction. Consumption demand for cell culture test kits will witness a growth rate of 7.2% in 2016 over 2015.

Diagnostic centers end user segment is expected to register highest CAGR in terms of revenue, accounting for US $ 392.8 Mn in terms of revenue in 2016. The increasing number of diagnostics centers, worldwide and a large number of patient pool depending on diagnostics centers for diagnosis of infectious diseases is expected to increase demand for diagnostics tests among diagnostics centers. The diagnostics centers end user segment will witness a growth rate of 7.4% in 2016 over 2015.

Access Full Report @  https://www.persistencemarketresearch.com/checkout/11413

Becton, Dickinson and Company, Cepheid, Inc. Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin SpA, Quidel Corporation, and Bio-Rad Laboratories, Inc are key players in the market. Top players are focusing on developing new products and improving sensitivity and specificity of the test kits. Collaborations and joint ventures among manufacturers and local governments are key business strategies being adopted to increase market share.

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl